Tag: Novo Nordisk

Novo Nordisk Announce Q1 Financial Results

Novo Nordisk
Danish drugmaker Novo Nordisk beat first-quarter operating profit forecasts on Friday, helped by higher sales of its biggest new drug hope, a treatment for type 2 diabetes. With Novo’s traditional ...

Support of Haemophilia Parients in Azerbaijan

Haemophilia patients are covered by Azerbaijan government not only through providing free of charge medicines but also being supported to have healthy and high quality of life. This topic was highl...

Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration

Gilead Sciences, Inc. and Novo Nordisk A/S announced that the companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis (N...

Teva to Launch Generis of Novo Nordisk Non-Insulin Med

Novo Nordisk today announced that a settlement between Novo Nordisk and Teva Pharmaceuticals USA, Inc. (Teva) has been reached on the US patent litigation case for Victoza® (liraglutide). Consequently...

Novo Nordisk Submitted Label Updates for its Insulin Aspart

Novo Nordisk announced that it has submitted label updates to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for Fiasp® (fast-acting insulin aspart), seeking approva...

Abbott and Novo Nordisk Team Up

Collaboration will enable insulin data to be shared between Novo Nordisk connected insulin pens and digital health tools compatible with FreeStyle Libre portfolio of products. Abbott and Novo Nordi...

Abbott and Novo Nordisk in Partnership

Abbott and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools...

FDA Approved Haemophilia A of Novo Nordisk

Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application for ESPEROCT® for the treatment of adults and children with haemophilia A. ESPER...

Novo Nordisk Expects Fast-Track Review for New Semaglutide

Novo Nordisk has said it is accelerating launch preparations for its new diabetes pill semaglutide, after investing in a voucher that will allow a fast review of the drug in the US. The FDA grants ...

Drug Giants Should Explain High Prices on Insulin

Sanofi, Eli Lilly and Novo Nordisk have been sent letters by US lawmakers requesting information on the increased costs of insulin in recent years and the companies’ profit from sales of these product...

Novo Nordisk Expands to 11 Markets across Asia Pacific

novo nordisk
Danish pharma company and the Swiss market expansion expert have partnered to provide high-quality cGMP quaternary ammonium compounds in eleven markets across the region. DKSH’s Business Unit Perfo...

Dutch biotech signs drug development agreement with Novo Nordisk

lab
Staten Biotechnology and Novo Nordisk have entered into a collaboration and exclusive option agreement to develop novel therapeutics for the treatment of hypertriglyceridaemia.

Novo Nordisk got the Beacon® Optofluidic platform

Berkeley Lights, Inc. and Novo Nordisk today announced that Novo Nordisk has purchased the Beacon® Optofluidic platform to accelerate workflows in cell line development and to use the platform for fut...

Novo Nordisk signed a Deal with e-Therapeutics to find Therapies for diabetes

e-Therapeutics will work with Novo for a year and use its technology to identify novel intervention strategies, biological pathways and compounds that could form the basis of new therapies. The UK ...

Novo Nordisk to invest $22 million in its US facility

Novo Nordisk
Novo Nordisk(Denmark), the world’s leading diabetes care company, will invest $22 million at its Clayton facility in Johnston County (North Carolina, USA). The move comes just ten months after Novo...

Novo Nordisk starts research collaboration with Embark Biotech

novo nordisk
Embark Biotech and Novo Nordisk entered into a research collaboration focusing on the discovery of novel treatments for obesity and its associated metabolic pathologies.